看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。
' S2 X/ _3 K* n- |6 ]7 U# q1 e' c0 U
# B6 I, t1 z1 s( P& s5 o" y+ k3 w! y, ^7 B/ k- Y z0 |% o
Currently available feasibility data for possible combination strategies.
2 b$ p2 A. D. O, @————————————————————————————————
- u# r# R/ @. F' B* OCombination Feasibility according to preliminary data
9 f; |5 V @( u: r. i: g9 o! Q; n——————————————————————————————————- Q" f J* h x: C, E
Bevacizumab + sorafenib Yes, reduced dose
+ F0 i8 K! d+ w: zBevacizumab + sunitinib† No , Q: e; w+ t: C- j4 t( U. Y0 w$ M
Bevacizumab + temsirolimus Yes
- M/ E7 y$ Y! _6 D( ~Bevacizumab + everolimus Yes
/ `8 Q! @+ Z8 J) k$ tSorafenib + sunitinib ?
- t% o" _3 L+ N _Sorafenib + temsirolimus Yes, reduced dose 8 O V8 {( N6 |+ ?
Sorafenib + everolimus Yes, reduced dose 2 C) g0 b+ v5 `8 R) w6 u" n
Sunitinib + temsirolimus† No
3 i9 r' A @' q N9 y, LSunitinib + everolimus ? * M! g( z' P- Q% b* O/ A1 l% i
Temsirolimus + everolimus ?
" e" ]7 Q$ M/ l; X$ u$ W————————————————————
4 P# m0 b6 K2 b& O+ L; `& [+ r†Led to US FDA warning.
' P4 f8 Q9 c3 ]?: As yet unattempted combination.. x: n8 i' E2 n# M! H& o) d! V
|